Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...